Which antipsychotic works best for lewy body psychosis? new trial aims to find out

NCT ID NCT05590637

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study compares two antipsychotic drugs, pimavanserin and quetiapine, to see which one better reduces hallucinations and delusions in people with Parkinson's disease or dementia with Lewy bodies. About 94 participants will be randomly assigned to one of the two medications, and their symptoms will be tracked using a standard questionnaire. The goal is to provide real-world guidance for doctors choosing between these treatments.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
pimavanserin (Nuplazid) and quetiapine (Seroquel)
What this could lead to
If it works, this could help doctors choose the best antipsychotic for managing hallucinations and delusions in people with Lewy body disease.
What could go wrong
This is a small, early-phase trial with only 94 participants, so results may not apply to everyone. Both drugs have known side effects, and the study compares existing treatments, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Delusions Hallucinations Lewy body dementia Lewy Body Disease Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UT Health Science Center - San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • University Health System

    RECRUITING

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.